• da Fonseca Leonardo Gomes LG Cancer Institute of Sao Paulo State, University of Sao Paulo, Av. Dr. Arnaldo 251, São Paulo, São Paulo, Brazil, leogfonseca@hotmail.com., Romulado Barroso-Sousa, Afonso da Silva Alves Bento, Bruna Paccola Blanco, Gabriel Luis Valente, Tulio Eduardo Flesch Pfiffer, Paulo Marcelo Hoff, and Jorge Sabbaga.
• Cancer Institute of Sao Paulo State, University of Sao Paulo, Av. Dr. Arnaldo 251, São Paulo, São Paulo, Brazil, leogfonseca@hotmail.com.
• Med. Oncol. 2014 Nov 1; 31 (11): 264.

AbstractSorafenib is the first systemic therapy to demonstrate survival benefit in advanced hepatocellular carcinoma (HCC) in randomized controlled trials with rigorous patient selection. Neutrophil-to-lymphocyte ratio (NLR) has been shown to be associated with poor survival in various solid tumors. Our aim is to evaluate the prognostic role of NLR in HCC patients treated with sorafenib. A total of 105 advanced HCC patients treated with sorafenib were retrospectively reviewed, and relevant data from the clinical records were collected. Univariate and multivariate analysis were carried out to identify factors associated with survival. The median age of the cohort was 59.7 years, and 84.8 % were Child-Pugh class A, and 86.7 % had ECOG performance status 0 or 1. Median duration of sorafenib treatment was 100 days. Median overall survival (OS) of the entire cohort was 8.03 months. Median OS was 5.23 months (95 % CI 2.96-7.50 months) and 10.05 months (95 % IC 2.52-18.47 months) for patients with NLR > 3.5 and NLR ≤ 3.5, respectively (p = 0.002). Alpha-fetoprotein >1,030 ng/mL and serum albumin ≤3.8 g/dL were also associated with worse prognosis (p = 0.006 and p = 0.042, respectively). The subgroup of patients with high alpha-fetoprotein, low albumin and NLR > 3.5 had median OS of 1.7 months, whereas the subgroup with none of these parameters had median OS of 16.5 months (p < 0.001). NLR affects survival in advanced HCC patients treated with sorafenib. Selecting HCC patients based on the laboratorial features may improve the therapeutic effectiveness of sorafenib.

38 keywords...

hide…